{"id":"zuclopenthixol","rwe":[],"tags":[{"label":"High Risk QT Prolonging Agents","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"5-hydroxytryptamine receptor 6","category":"target"},{"label":"HTR6","category":"gene"},{"label":"HTR2A","category":"gene"},{"label":"ADRA1A","category":"gene"},{"label":"N05AF05","category":"atc"},{"label":"Active","category":"status"},{"label":"Schizophrenia","category":"indication"},{"label":"Antipsychotic Agents","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Central Nervous System Depressants","category":"pharmacology"},{"label":"Dopamine Agents","category":"pharmacology"},{"label":"Dopamine Antagonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Psychotropic Drugs","category":"pharmacology"},{"label":"Tranquilizing Agents","category":"pharmacology"}],"phase":"discontinued","safety":{"safetySignals":[{"llr":1057.142,"date":"","count":202,"signal":"Blood prolactin abnormal","source":"DrugCentral FAERS","actionTaken":"Reported 202 times (LLR=1057)"},{"llr":1048.309,"date":"","count":202,"signal":"Anosognosia","source":"DrugCentral FAERS","actionTaken":"Reported 202 times (LLR=1048)"},{"llr":973.976,"date":"","count":201,"signal":"Disturbance in social behaviour","source":"DrugCentral FAERS","actionTaken":"Reported 201 times (LLR=974)"},{"llr":911.936,"date":"","count":213,"signal":"Sexual dysfunction","source":"DrugCentral FAERS","actionTaken":"Reported 213 times (LLR=912)"},{"llr":862.18,"date":"","count":207,"signal":"Metabolic disorder","source":"DrugCentral FAERS","actionTaken":"Reported 207 times (LLR=862)"},{"llr":771.338,"date":"","count":191,"signal":"Personality change","source":"DrugCentral FAERS","actionTaken":"Reported 191 times (LLR=771)"},{"llr":750.648,"date":"","count":218,"signal":"Dystonia","source":"DrugCentral FAERS","actionTaken":"Reported 218 times (LLR=751)"},{"llr":608.937,"date":"","count":234,"signal":"Sedation","source":"DrugCentral FAERS","actionTaken":"Reported 234 times (LLR=609)"},{"llr":588.394,"date":"","count":220,"signal":"Dyskinesia","source":"DrugCentral FAERS","actionTaken":"Reported 220 times (LLR=588)"},{"llr":500.012,"date":"","count":233,"signal":"Suicide attempt","source":"DrugCentral FAERS","actionTaken":"Reported 233 times (LLR=500)"},{"llr":354.514,"date":"","count":210,"signal":"Blood glucose increased","source":"DrugCentral FAERS","actionTaken":"Reported 210 times (LLR=355)"},{"llr":307.805,"date":"","count":103,"signal":"Schizophrenia","source":"DrugCentral FAERS","actionTaken":"Reported 103 times (LLR=308)"},{"llr":199.447,"date":"","count":61,"signal":"Insurance issue","source":"DrugCentral FAERS","actionTaken":"Reported 61 times (LLR=199)"},{"llr":188.763,"date":"","count":82,"signal":"Neuroleptic malignant syndrome","source":"DrugCentral FAERS","actionTaken":"Reported 82 times (LLR=189)"},{"llr":170.642,"date":"","count":83,"signal":"Intentional self-injury","source":"DrugCentral FAERS","actionTaken":"Reported 83 times (LLR=171)"}],"drugInteractions":[{"url":"/drug/high-risk-qt-prolonging-agents","drug":"High Risk QT Prolonging Agents","action":"Avoid combination","effect":"Highest Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents","source":"DrugCentral","drugSlug":"high-risk-qt-prolonging-agents"}],"commonSideEffects":[{"effect":"Blood prolactin abnormal","drugRate":"LLR 1057","severity":"serious"},{"effect":"Anosognosia","drugRate":"LLR 1048","severity":"serious"},{"effect":"Disturbance in social behaviour","drugRate":"LLR 974","severity":"serious"},{"effect":"Sexual dysfunction","drugRate":"LLR 912","severity":"serious"},{"effect":"Metabolic disorder","drugRate":"LLR 862","severity":"serious"},{"effect":"Personality change","drugRate":"LLR 771","severity":"serious"},{"effect":"Dystonia","drugRate":"LLR 751","severity":"serious"},{"effect":"Sedation","drugRate":"LLR 609","severity":"serious"},{"effect":"Dyskinesia","drugRate":"LLR 588","severity":"serious"},{"effect":"Suicide attempt","drugRate":"LLR 500","severity":"serious"},{"effect":"Blood glucose increased","drugRate":"LLR 355","severity":"common"},{"effect":"Schizophrenia","drugRate":"LLR 308","severity":"common"},{"effect":"Insurance issue","drugRate":"LLR 199","severity":"common"},{"effect":"Neuroleptic malignant syndrome","drugRate":"LLR 189","severity":"common"},{"effect":"Intentional self-injury","drugRate":"LLR 171","severity":"common"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"clopixol","offLabel":[],"synonyms":["zuclopenthixol","(Z)-Clopenthixol","cisordinol","clopixol","zuclopenthixol dihydrochloride","zuclopenthixol hydrochloride","zuclopenthixol HCl"],"timeline":[],"approvals":[{"date":"","orphan":false,"company":"","regulator":"UK Medicines and Healthcare Products Regulatory Agency (MHRA)"}],"brandName":"Clopixol","ecosystem":[{"indication":"Schizophrenia","otherDrugs":[{"name":"aripiprazole","slug":"aripiprazole","company":"Otsuka"},{"name":"aripiprazole lauroxil","slug":"aripiprazole-lauroxil","company":"Alkermes"},{"name":"asenapine","slug":"asenapine","company":"Forest Labs Inc"},{"name":"brexpiprazole","slug":"brexpiprazole","company":"Otsuka Pharm Co Ltd"}],"globalPrevalence":24000000}],"mechanism":{"target":"5-hydroxytryptamine receptor 6","targets":[{"gene":"HTR6","source":"DrugCentral","target":"5-hydroxytryptamine receptor 6","protein":"5-hydroxytryptamine receptor 6"},{"gene":"HTR2A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2A","protein":"5-hydroxytryptamine receptor 2A"},{"gene":"ADRA1A","source":"DrugCentral","target":"Alpha-1A adrenergic receptor","protein":"Alpha-1A adrenergic receptor"},{"gene":"DRD1","source":"DrugCentral","target":"D(1A) dopamine receptor","protein":"D(1A) dopamine receptor"},{"gene":"DRD2","source":"DrugCentral","target":"D(2) dopamine receptor","protein":"D(2) dopamine receptor"}],"modality":"Small Molecule","drugClass":"High Risk QT Prolonging Agents","explanation":"Imagine your brain is like a city with many different streets and intersections. The 5-hydroxytryptamine receptor 6 is like a traffic light that helps control the flow of information between different parts of the brain. By blocking this receptor, Clopixol helps to reduce the 'traffic' of abnormal signals that can contribute to symptoms of schizophrenia.","oneSentence":"Clopixol works by blocking the 5-hydroxytryptamine receptor 6, which helps to regulate mood and reduce symptoms of schizophrenia.","technicalDetail":"Clopixol is a selective antagonist of the 5-hydroxytryptamine receptor 6 (5-HT6), a subtype of serotonin receptor that plays a role in regulating dopamine release and modulating cognitive and motor functions."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2877","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ZUCLOPENTHIXOL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ZUCLOPENTHIXOL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T16:16:42.269150","biosimilars":[],"competitors":[{"drugName":"chlorprothixene","drugSlug":"chlorprothixene","fdaApproval":"1967-06-19","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"thiothixene","drugSlug":"thiothixene","fdaApproval":"1967-07-24","genericCount":7,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"zuclopenthixol","indications":{"approved":[{"name":"Schizophrenia","source":"DrugCentral","snomedId":58214004,"regulator":"FDA","usPrevalence":2800000,"globalPrevalence":24000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2022"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"chlorprothixene","brandName":"chlorprothixene","genericName":"chlorprothixene","approvalYear":"1967","relationship":"same-class"},{"drugId":"thiothixene","brandName":"thiothixene","genericName":"thiothixene","approvalYear":"1967","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05766007","phase":"","title":"Long-acting Injectable Antipsychotics for Mental Ill-Health in Pregnancy and Postpartum","status":"RECRUITING","sponsor":"University of Liverpool","startDate":"2023-08-01","conditions":["Schizophrenia","Psychosis","Mania","Pregnancy","Drug Exposure in Utero","Drug Exposure Via Breast Milk","Antipsychotic Agents","Breastfeeding"],"enrollment":125,"completionDate":"2026-06-30"},{"nctId":"NCT07047651","phase":"PHASE4","title":"Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR.","status":"RECRUITING","sponsor":"Dr. Stavroula Rakitzi","startDate":"2025-06-04","conditions":["Treatment Resistant Schizophrenia","Treatment Resistant Bipolar Disorder"],"enrollment":40,"completionDate":"2027-12-20"},{"nctId":"NCT07152184","phase":"PHASE2","title":"Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patients With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2026-01-01","conditions":["Patient With Schizophrenia Spectrum Disorder","NLM Classification WM 203, Psychology:Schizophrenic Psychology","Schizophrenia Spectrum and Other Psychotic Disorders"],"enrollment":288,"completionDate":"2032-02-01"},{"nctId":"NCT02307396","phase":"PHASE4","title":"Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2015-02-01","conditions":["Schizophrenia","Schizophrenia and Disorders With Psychotic Features","Schizoaffective Disorders"],"enrollment":21,"completionDate":"2016-06-22"},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":["Dementia","Depression","Schizophrenia","Psychosomatic Disorders","Anxiety Disorders"],"enrollment":407,"completionDate":"2017-06-28"},{"nctId":"NCT02582736","phase":"","title":"Antipsychotics and Risk of Hyperglycemic Emergencies","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2012-04","conditions":["Psychotic Disorders","Schizophrenia","Schizoaffective Disorder","Bipolar Disorder","Diabetes Mellitus, Type 2"],"enrollment":725489,"completionDate":"2012-12"},{"nctId":"NCT01765829","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2012-11","conditions":["Psychosis Nos/Other"],"enrollment":104,"completionDate":"2015-11"},{"nctId":"NCT01323205","phase":"PHASE2","title":"Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-05","conditions":["Schizophrenia"],"enrollment":100,"completionDate":"2012-12"},{"nctId":"NCT00206960","phase":"NA","title":"Dopaminergic, Functional, Structural, and Cognitive Disturbances in First-episode Schizophrenia","status":"COMPLETED","sponsor":"Birte Glenthoj","startDate":"1998-01","conditions":["Schizophrenia"],"enrollment":56,"completionDate":"2010-09"},{"nctId":"NCT00767715","phase":"PHASE4","title":"A Study in the Treatment of Acute Mania","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2004-10","conditions":["Bipolar Disorder"],"enrollment":11,"completionDate":"2005-04"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"004069","UNII":"47ISU063SG","CHEBI":"CHEBI:51364","INN_ID":"5443","RXNORM":"102546","UMLSCUI":"C0376160","ChEMBL_ID":"CHEMBL53904","KEGG_DRUG":"D03556","DRUGBANK_ID":"DB01624","PUBCHEM_CID":"5311507","SNOMEDCT_US":"387566002","IUPHAR_LIGAND_ID":"7559","SECONDARY_CAS_RN":"58045-23-1","MESH_DESCRIPTOR_UI":"D003006"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"49%"},"publicationCount":347,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N05AF05","allCodes":["N05AF05"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"discontinued","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clopixol, also known as Zuclopenthixol, is a high-risk QT prolonging agent used to treat schizophrenia. It is a small molecule that targets the 5-hydroxytryptamine receptor 6. The commercial status of Clopixol is unclear, but it is likely patented. Key safety considerations include its potential to prolong the QT interval, which can increase the risk of serious cardiac arrhythmias. Clopixol is not FDA-approved, but it is approved for use in some countries to treat schizophrenia.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"OTHER","regulator":"UK Medicines and Healthcare Products Regulatory Agency (MHRA)","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}